pharmaphorum April 29, 2024
Japan’s Ono Pharma has bolstered its cancer pipeline with a $2.4 billion agreement to buy Deciphera Pharma of the US and its fast-growing gastrointestinal stromal tumour (GIST) therapy Qinlock.
Ono is offering $26.50 per share in cash for the Waltham, Massachusetts-based company, saying the deal will enable it to “build a robust presence in oncology,” one of the group’s key priority areas.
KIT inhibitor Qinlock (ripretinib) is approved in more than 40 countries around the world as a fourth-line therapy for GIST in adults who have received prior treatment with three or more kinase inhibitor therapies.
Deciphera’s efforts to move it earlier in the treatment pathway have suffered some setbacks, but the drug still grew 27% to $159 million last...
Today's Sponsors
Today's Sponsor